SEC Comment Letter for OKYO Pharma (OKYO) — Feb 6, 2026
OKYO Pharma Ltd
Date: Feb. 6, 2026 · CIK: 0001849296 · Accession: 0000000000-26-001302
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293145
Letter
Re: OKYO Pharma Limited Registration Statement on Form F-3 Filed February 2, 2026 File No. 333-293145 Dear Robert J. Dempsey:
February 6, 2026
Robert J. Dempsey Chief Executive Officer and Director OKYO Pharma Limited Martello Court Admiral Park St. Peter Port Guernsey GY1 3HB
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Anna Tomczyk, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> February 6, 2026 Robert J. Dempsey Chief Executive Officer and Director OKYO Pharma Limited Martello Court Admiral Park St. Peter Port Guernsey GY1 3HB Re: OKYO Pharma Limited Registration Statement on Form F-3 Filed February 2, 2026 File No. 333-293145 Dear Robert J. Dempsey: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Anna Tomczyk, Esq. </TEXT> </DOCUMENT>